Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-02-23

AUTHORS

F. Petrelli, S. Barni, Anti-EGFR agents for liver metastases

ABSTRACT

BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p = 0.0001), the R0 resection rate from 11% to 18% (RR 1.59, p = 0.04) and PFS (HR 0.68, p = 0.002), but not OS (p = 0.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases. More... »

PAGES

997-1004

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2

DOI

http://dx.doi.org/10.1007/s00384-012-1438-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046464035

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22358385


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cetuximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Mutational Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Panitumumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Publication Bias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ras Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417270.7", 
          "name": [
            "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrelli", 
        "givenName": "F.", 
        "id": "sg:person.0661567716.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661567716.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417270.7", 
          "name": [
            "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barni", 
        "givenName": "S.", 
        "id": "sg:person.0645550356.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Anti-EGFR agents for liver metastases", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6605259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048476579", 
          "https://doi.org/10.1038/sj.bjc.6605259"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-02-23", 
    "datePublishedReg": "2012-02-23", 
    "description": "BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p\u2009=\u20090.0001), the R0 resection rate from 11% to 18% (RR 1.59, p\u2009=\u20090.04) and PFS (HR 0.68, p\u2009=\u20090.002), but not OS (p\u2009=\u20090.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00384-012-1438-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096381", 
        "issn": [
          "0179-1958", 
          "1432-1262"
        ], 
        "name": "International Journal of Colorectal Disease", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "metastatic colorectal cancer", 
      "overall response rate", 
      "KRAS wild-type patients", 
      "R0 resection rate", 
      "wild-type patients", 
      "resection rate", 
      "hazard ratio", 
      "relative risk", 
      "KRAS wild-type metastatic colorectal cancer", 
      "liver-limited metastatic colorectal cancer", 
      "response rate", 
      "wild-type metastatic colorectal cancer", 
      "unresectable metastatic colorectal cancer", 
      "unresectable liver-limited disease", 
      "colorectal liver-limited metastases", 
      "liver-limited disease", 
      "liver-limited metastases", 
      "unresectable liver metastases", 
      "Cochrane Central Register", 
      "risk of progression", 
      "anti-EGFR agents", 
      "chemotherapy plus", 
      "ResultsFour RCTs", 
      "radical resection", 
      "Central Register", 
      "overall survival", 
      "liver metastases", 
      "Controlled Trials", 
      "colorectal cancer", 
      "patients", 
      "confidence intervals", 
      "conversion therapy", 
      "RCTs", 
      "survival", 
      "metastasis", 
      "trials", 
      "risk", 
      "ConclusionsThe addition", 
      "BackgroundCetuximab", 
      "resectability", 
      "panitumumab", 
      "resection", 
      "chemotherapy", 
      "EMBASE", 
      "MEDLINE", 
      "PFS", 
      "therapy", 
      "KRAS", 
      "cancer", 
      "MethodsWe", 
      "disease", 
      "progression", 
      "rate", 
      "outcomes", 
      "Register", 
      "OS", 
      "agents", 
      "interval", 
      "addition", 
      "Plus", 
      "effect", 
      "combination", 
      "data", 
      "ratio", 
      "choice", 
      "materials"
    ], 
    "name": "Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis", 
    "pagination": "997-1004", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046464035"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00384-012-1438-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22358385"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00384-012-1438-2", 
      "https://app.dimensions.ai/details/publication/pub.1046464035"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_581.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00384-012-1438-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      21 PREDICATES      110 URIs      101 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00384-012-1438-2 schema:about N0de73a950adf42c5a9d084f55db4d44b
2 N29e19d3055fe45a8ae409748c89b5af4
3 N3fcecf19debb4d14b88c29a22096cd2e
4 N506d7314eb8647f29ecab25ec2079bf3
5 N5292517fec9f424daa0189d7f75dd747
6 N574021645ff642929893c7145947de49
7 N5e5626bbfa7e4481aa87a9dc9e32528e
8 N61c49f82a44e470f8b5b5a08d56f5eb6
9 N8020924ffb014ac19a1da16941f10fd3
10 Na476335ddc124579804ffd4ffa392996
11 Nb2ddbcfeb77f44858fc6f4afb45ac39e
12 Nb859c96f84e24c8db5bcda39ede1f882
13 Nc2dfb36514a84ef18e31e482d9ffbe07
14 Nd48df4f6d90f4e90bf5e76597a714bd9
15 Nd6b0da47c884448b8d954a6f0164bebf
16 Nd7eac77a77764e2a97ddb3b3be60bec6
17 Nea722884911f41a7a198a59f2246dfb4
18 Nefc03d2507df410cbbbe00645888c576
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nff1e3ba4735a415695a42475837a157a
22 schema:citation sg:pub.10.1038/sj.bjc.6605259
23 schema:datePublished 2012-02-23
24 schema:datePublishedReg 2012-02-23
25 schema:description BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p = 0.0001), the R0 resection rate from 11% to 18% (RR 1.59, p = 0.04) and PFS (HR 0.68, p = 0.002), but not OS (p = 0.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N6e092d71d8664e178fc7fc4708565ceb
29 Na912800f7073416199364d73095d9a69
30 sg:journal.1096381
31 schema:keywords BackgroundCetuximab
32 Central Register
33 Cochrane Central Register
34 ConclusionsThe addition
35 Controlled Trials
36 EMBASE
37 KRAS
38 KRAS wild-type metastatic colorectal cancer
39 KRAS wild-type patients
40 MEDLINE
41 MethodsWe
42 OS
43 PFS
44 Plus
45 R0 resection rate
46 RCTs
47 Register
48 ResultsFour RCTs
49 addition
50 agents
51 anti-EGFR agents
52 cancer
53 chemotherapy
54 chemotherapy plus
55 choice
56 colorectal cancer
57 colorectal liver-limited metastases
58 combination
59 confidence intervals
60 conversion therapy
61 data
62 disease
63 effect
64 hazard ratio
65 interval
66 liver metastases
67 liver-limited disease
68 liver-limited metastases
69 liver-limited metastatic colorectal cancer
70 materials
71 metastasis
72 metastatic colorectal cancer
73 outcomes
74 overall response rate
75 overall survival
76 panitumumab
77 patients
78 progression
79 radical resection
80 rate
81 ratio
82 relative risk
83 resectability
84 resection
85 resection rate
86 response rate
87 risk
88 risk of progression
89 survival
90 therapy
91 trials
92 unresectable liver metastases
93 unresectable liver-limited disease
94 unresectable metastatic colorectal cancer
95 wild-type metastatic colorectal cancer
96 wild-type patients
97 schema:name Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis
98 schema:pagination 997-1004
99 schema:productId N923906094a134cb7b93bdf6537e79a00
100 Nf02a3eb3325c4b2ebf5f72f4e807d5e7
101 Nf8da3ef2beef40b7992ec0c6f2ec72a9
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046464035
103 https://doi.org/10.1007/s00384-012-1438-2
104 schema:sdDatePublished 2022-08-04T17:00
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher Nbfc975e15ea54a3bbce74245a4b63dbc
107 schema:url https://doi.org/10.1007/s00384-012-1438-2
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N0de73a950adf42c5a9d084f55db4d44b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 N10a02e14899744c5b544a87e500f4c36 rdf:first N1c3786abdbec4d86a5475ab737184c96
115 rdf:rest rdf:nil
116 N1c3786abdbec4d86a5475ab737184c96 schema:familyName Anti-EGFR agents for liver metastases
117 rdf:type schema:Person
118 N227b7093c4b7419087e1ce49033bbde7 rdf:first sg:person.0645550356.01
119 rdf:rest N10a02e14899744c5b544a87e500f4c36
120 N29e19d3055fe45a8ae409748c89b5af4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Antibodies, Monoclonal
122 rdf:type schema:DefinedTerm
123 N3fcecf19debb4d14b88c29a22096cd2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cetuximab
125 rdf:type schema:DefinedTerm
126 N506d7314eb8647f29ecab25ec2079bf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Proto-Oncogene Proteins p21(ras)
128 rdf:type schema:DefinedTerm
129 N5292517fec9f424daa0189d7f75dd747 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name ErbB Receptors
131 rdf:type schema:DefinedTerm
132 N574021645ff642929893c7145947de49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Disease-Free Survival
134 rdf:type schema:DefinedTerm
135 N5e5626bbfa7e4481aa87a9dc9e32528e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Randomized Controlled Trials as Topic
137 rdf:type schema:DefinedTerm
138 N61c49f82a44e470f8b5b5a08d56f5eb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Risk
140 rdf:type schema:DefinedTerm
141 N6e092d71d8664e178fc7fc4708565ceb schema:volumeNumber 27
142 rdf:type schema:PublicationVolume
143 N8020924ffb014ac19a1da16941f10fd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Proto-Oncogene Proteins
145 rdf:type schema:DefinedTerm
146 N923906094a134cb7b93bdf6537e79a00 schema:name dimensions_id
147 schema:value pub.1046464035
148 rdf:type schema:PropertyValue
149 Na476335ddc124579804ffd4ffa392996 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Liver Neoplasms
151 rdf:type schema:DefinedTerm
152 Na912800f7073416199364d73095d9a69 schema:issueNumber 8
153 rdf:type schema:PublicationIssue
154 Nb2ddbcfeb77f44858fc6f4afb45ac39e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name ras Proteins
156 rdf:type schema:DefinedTerm
157 Nb859c96f84e24c8db5bcda39ede1f882 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Antibodies, Monoclonal, Humanized
159 rdf:type schema:DefinedTerm
160 Nbfc975e15ea54a3bbce74245a4b63dbc schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 Nc2dfb36514a84ef18e31e482d9ffbe07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Treatment Outcome
164 rdf:type schema:DefinedTerm
165 Nd48df4f6d90f4e90bf5e76597a714bd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Panitumumab
167 rdf:type schema:DefinedTerm
168 Nd6b0da47c884448b8d954a6f0164bebf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Publication Bias
170 rdf:type schema:DefinedTerm
171 Nd7eac77a77764e2a97ddb3b3be60bec6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Colorectal Neoplasms
173 rdf:type schema:DefinedTerm
174 Nea722884911f41a7a198a59f2246dfb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antineoplastic Agents
176 rdf:type schema:DefinedTerm
177 Nefc03d2507df410cbbbe00645888c576 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name DNA Mutational Analysis
179 rdf:type schema:DefinedTerm
180 Nf02a3eb3325c4b2ebf5f72f4e807d5e7 schema:name pubmed_id
181 schema:value 22358385
182 rdf:type schema:PropertyValue
183 Nf8da3ef2beef40b7992ec0c6f2ec72a9 schema:name doi
184 schema:value 10.1007/s00384-012-1438-2
185 rdf:type schema:PropertyValue
186 Nff1e3ba4735a415695a42475837a157a rdf:first sg:person.0661567716.40
187 rdf:rest N227b7093c4b7419087e1ce49033bbde7
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1096381 schema:issn 0179-1958
195 1432-1262
196 schema:name International Journal of Colorectal Disease
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.0645550356.01 schema:affiliation grid-institutes:grid.417270.7
200 schema:familyName Barni
201 schema:givenName S.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01
203 rdf:type schema:Person
204 sg:person.0661567716.40 schema:affiliation grid-institutes:grid.417270.7
205 schema:familyName Petrelli
206 schema:givenName F.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661567716.40
208 rdf:type schema:Person
209 sg:pub.10.1038/sj.bjc.6605259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048476579
210 https://doi.org/10.1038/sj.bjc.6605259
211 rdf:type schema:CreativeWork
212 grid-institutes:grid.417270.7 schema:alternateName Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
213 schema:name Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...